Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1999 1
2000 3
2001 6
2002 2
2003 1
2004 2
2005 2
2006 1
2007 1
2009 3
2010 8
2011 1
2012 1
2013 2
2015 2
2016 6
2017 4
2018 4
2020 3
2021 4
2022 3
2023 4
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I; French CF Reference Network study group. Dreano E, et al. Among authors: mely l. Eur Respir J. 2023 Oct 19;62(4):2300110. doi: 10.1183/13993003.00110-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37696564
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C; French Cystic Fibrosis Reference Network study group. Burgel PR, et al. Among authors: mely l. Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13. Lancet Respir Med. 2024. PMID: 39151434
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Burgel PR, Paillasseur JL, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Burnet E, Ouaalaya EH, Sogni P, Da Silva J, Martin C; Participating Investigators of the French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Among authors: mely l. Ann Am Thorac Soc. 2024 Jul;21(7):1053-1064. doi: 10.1513/AnnalsATS.202312-1065OC. Ann Am Thorac Soc. 2024. PMID: 38579175
[Inhalers and nebulizers in the children].
David V, Mély L, Siret D, Dubus JC. David V, et al. Among authors: mely l. Arch Pediatr. 2002 Aug;9 Suppl 3:415s-421s. doi: 10.1016/s0929-693x(02)00153-7. Arch Pediatr. 2002. PMID: 12205818 Review. French.
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Among authors: mely l. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738
[Physical activity and exercise training for patients with cystic fibrosis].
Karila C, Ravilly S, Gauthier R, Tardif C, Neveu H, Maire J, Ramel S, Cracowski C, Legallais P, Foure H, Halm AM, Saugier J, Bordas G, Loire N, Kirszenbaum M, Dassonville J, Mely L, Wuyam B, Giovannetti P, Ouksel H, Ellaffi M, Denjean A; groupe de travail de la Société francaise de la mucoviscidose. Karila C, et al. Among authors: mely l. Rev Mal Respir. 2010 Apr;27(4):301-13. doi: 10.1016/j.rmr.2010.02.012. Epub 2010 Mar 30. Rev Mal Respir. 2010. PMID: 20403541 Review. French.
Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.
Campredon A, Battistella E, Martin C, Durieu I, Mely L, Marguet C, Belleguic C, Murris-Espin M, Chiron R, Fanton A, Bui S, Reynaud-Gaubert M, Reix P, Hoang-Thi TN, Vakalopoulou M, Revel MP, Da Silva J, Burgel PR, Chassagnon G; Participating investigators in the French CF reference network study group:; Mounard J, Poulet C, Rames Amiens C, Person C, Troussier F, Urban Angers T, Dalphin ML, Dalphin JC, Pernet D, Richaud-Thiriez Besançon B, Bui S, Fayon M, Macey-Caro Bordeaux J, Campbell K, Laurans Caen M, Borderon C, Heraud MC, Labbé A, Montcouquiol Clermont-Ferrand S, Bassinet L, Remus Créteil N, Fanton A, Houzel-Charavel A, Huet F, Perez-Martin Dijon S, Boldron-Ghaddar A, Scalbert Dunkerque M, Mely Giens L, Camara B, Llerena C, Pin I, Quétant Grenoble S, Cottereau A, Deschildre A, Gicquello A, Perez T, Stervinou-Wemeau L, Thumerelle C, Wallaert B, Wizla Lille N, Languepin J, Ménétrey C, Dupuy-Grasset Limoges M, Bazus L, Buchs C, Jubin V, Werck-Gallois MC, Mainguy C, Perrin T, Reix P, Toutain-Rigolet Lyon Pédiatrie A, Durieu I, Durupt S, Reynaud Q, Nove-Josserand Lyon Adultes R, Baravalle-Einaudi M, Coltey B, Dufeu N, Dubus JC, Stremler Marseille N, Caimmi D, Chiron Montpell… See abstract for full author list ➔ Campredon A, et al. Among authors: mely l. Eur Respir J. 2022 Jun 16;59(6):2101344. doi: 10.1183/13993003.01344-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34795038 Free article.
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Martin C, et al. Among authors: mely l. J Cyst Fibros. 2022 May;21(3):489-496. doi: 10.1016/j.jcf.2022.01.012. Epub 2022 Feb 2. J Cyst Fibros. 2022. PMID: 35123901 Free article.
61 results